TTHX1114

Trefoil Therapeutics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	TTHX1114
Sponsor	Trefoil Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Safety and Efficacy Trial of TTHX1114 in People With CED (PHASE2)
TTHX1114(NM141) in Combination With DWEK/DSO (PHASE2)
A Phase 1/ Phase 2 Study of TTHX1114(NM141) (PHASE1, PHASE2)
Dose Escalation TTHX1114 Ophthalmic Solution (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TTHX1114 CI brief — competitive landscape report
TTHX1114 updates RSS · CI watch RSS
Trefoil Therapeutics, Inc. portfolio CI